Multicenter trial of octreotide in patients with refractory acquired immunodeficiency syndrome-associated diarrhea
| Autor: | Jan M. Orenstein, Owen J. Smith, C. Mel Wilcox, Larry Eron, John J. Stern, Frank M. Graziano, John P. Cello, Gordon Dickerson, Kip Lyche, W. Jeffrey Fessel, Nezam H. Afdhal, Vonda Reeves-Darby, Timothy P. Flanigan, Jorge E. Valenzuela, Richard P. Levy, Paul Basuk, Ronald Fogel, Douglas Pleakow, Mark O. Loveless, Richard Goodgame, Michael D. Brown, James H. Grendell, Timothy T. Schubert, Douglas Simon, Maurizio Bonacini |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Adult
Diarrhea Male medicine.medical_specialty medicine.medical_treatment Octreotide Placebo Gastroenterology law.invention Randomized controlled trial Double-Blind Method law Multicenter trial Internal medicine medicine Humans Adverse effect Chemotherapy Acquired Immunodeficiency Syndrome Hepatology business.industry Surgery CD4 Lymphocyte Count Female medicine.symptom business Complication medicine.drug |
| Zdroj: | Gastroenterology. 108(6) |
| ISSN: | 0016-5085 |
| Popis: | Background/Aims: Diarrhea is a significant problem in patients with acquired immunodeficiency syndrome (AIDS). The aim of this study was to determine octreotide effectiveness in refractory AIDS-associated diarrhea. Methods: In a 3-week protocol, 129 patients with a stool weight of >500 g/day despite standard antidiarrheal therapy were randomized to receive octreotide or placebo (3:2 ratio). Octreotide dose was increased 100 μg weekly to a maximum of 300 μg three times a day based on weekly 72-hour stool collections. Subsequently, patients received open-label octreotide at doses of up to 500 μg three times a day. Results: A 30% decrease in stool weight defined response. After 3 weeks, 48% of octreotide- and 39% of placebo-treated patients had responded ( P = 0.43). At 300 μg three times a day, 50% of octreotide- and 30.1% of placebo-treated patients responded ( P = 0.12). At a baseline stool weight of 1000–2000 g/day, 57% of octreotide- and 25% of placebo-treated patients responded ( P = 0.06). Response rates based on CD4 counts, diarrhea duration, body weight, human immunodeficiency virus risk factor, and presence or absence of pathogens showed no benefit of octreotide. Adverse events were more frequent in the octreotide-treated group. Conclusion: In the doses studied, octreotide was not more effective than placebo in patients with refractory AIDS-associated diarrhea. This lack of effectiveness may be attributable to inadequate sample size, doses, and duration of study treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|